Royalty Pharma (RPRX) Reports Q4 Revenue of $594 million
Royalty Pharma plc (NASDAQ: RPRX) reported Q4 revenue of $594 million, versus $596 million reported last year.
2025 Financial Outlook
Royalty Pharma has provided guidance for full-year 2025, excluding new transactions and borrowings announced after the date of this release, as follows:
| Provided February 11, 2025 | |
| Portfolio Receipts | $2,900 million to $3,050 million (Growth of ~+4% to 9% year/year) |
| Payments for operating and professional costs | Approximately 10% of Portfolio Receipts(1) |
| Interest paid | $260 million |
The above Portfolio Receipts guidance represents expected growth of 4% to 9% in 2025. Royalty Pharma’s full-year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.
2025 guidance for payments for operating and professional costs and interest paid does not reflect the impact of the internalization transaction announced on January 10, 2025 and will be updated following the closing of the internalization transaction, which is expected to be in the second quarter of 2025.
Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and is anticipated to be approximately $260 million in 2025. Interest paid is anticipated to be approximately $138 million in the first quarter of 2025, which includes the first interest payment on the $1.5 billion notes issued in June 2024. Interest paid in the third quarter of 2025 is anticipated to be $119 million. De minimis amounts are anticipated in the second and fourth quarter of 2025. These projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility. In 2024, Royalty Pharma collected interest of $46 million on its cash and cash equivalents.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.